MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
Location of the MET mutation found in familial EGFR-mutant lung cancer.... | Download Scientific Diagram
The multiple paths towards MET receptor addiction in cancer | Oncogene
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - Lung Cancer
Immunotherapy in non-small cell lung cancer harbouring driver mutations - Cancer Treatment Reviews
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Mutational profiles in non-small cell lung cancer. (A) Oncogenic driver... | Download Scientific Diagram
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Research Increasingly Points to the Role of Molecular Diversity in Metastatic Lung Cancer - The ASCO Post
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations - Journal of Thoracic Oncology
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
Lung cancer with MET exon 14 skipping mutation | LCTT
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
